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Zusammenfassung
Hintergrund: Internationale und nationale Leitlinien (S3-
Leitlinie) empfehlen eine rein symptomorientierte Nach-
sorge, die hinsichtlich der apparativen Diagnostik allein
durch eine regelmäßige Mammographie erweitert wird.
Allerdings stößt diese Praxis, die in randomisierten
Untersuchungen einer intensivierten Nachsorge gleich-
wertig war, bei den Betroffenen immer wieder auf Un-
verständnis. Patientinnen und Methoden: Die vorliegen-
de Untersuchung zeigt die Sichtweise der Betroffenen
basierend auf den Ergebnissen einer Umfrage bei 2000
Patientinnen mit anamnestisch bekanntem Mammakar-
zinom. Ergebnisse: Insgesamt beantworteten 452 Patien-
tinnen (22,6%) den Fragebogen. Das mediane Alter der
Befragten betrug 62 Jahre (23–85 Jahre). Mehr als 80%
der Patientinnen waren zum Befragungszeitpunkt krank-
heitsfrei. Die Notwendigkeit der Nachsorge wurde von
der Mehrheit der Patientinnen bejaht (>95%), allerdings
wünschten knapp ein Drittel der Befragten eine mehr ap-
parativ ausgerichtete Nachsorge. Im Gegensatz zu den
Richtlinien zeigt diese Umfrage, dass die gegenwärtig
durchgeführten Nachsorgeuntersuchungen mit teils aus-
giebigen Laboruntersuchungen und bildgebenden Ver-
fahren erweitert werden. Schlussfolgerung: Diese Umfra-
ge offenbart eine klare Diskrepanz zwischen den Empfeh-
lungen und den tatsächlich durchgeführten Nachsor-
geuntersuchungen. Eine neue Nachsorgestudie, die den
Nutzen einer intensivierten Nachsorge vor dem Hinter-
grund innovativer Diagnostik- und Therapieverfahren
(z.B. Endokrinologie, Immuntherapie, Chemotherapie)
untersucht, ist notwendig.
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Summary
Background: International and national guidelines (S3
guideline) for the surveillance of post-treatment breast
cancer patients recommend a clinical follow-up includ-
ing routine history and physical examination and regular
mammograms. The practice of a clinical follow-up has
been often discussed, but has been proven not to be in-
ferior when compared to an intensified follow-up in ran-
domized trials. Patients and Methods: The present man-
uscript reports the patients’ view on the basis of a survey
including 2000 patients with a history of breast cancer.
Results: A total of 452 patients (22.6%) answered the
questionnaire. The median age was 62 years (range
23–85 years). More than 80% of the patients were dis-
ease-free at the time of the survey. The need for surveil-
lance was affirmed by the majority of patients (>95%),
and one third stated that there was a need for more tech-
nical efforts during follow-up. In contrast to the follow-up
guidelines, the results of the present survey indicated
that most of the regularly scheduled follow-up visits
were expanded using extensive laboratory and imaging
procedures. Conclusion: This survey shows that the ma-
jority of physicians obviously do not accept the present
follow-up guidelines. A new surveillance study investi-
gating the efficacy of an intensified surveillance based
on the improved possibilities of modern diagnostics and
endocrine, immunotherapeutic, chemotherapeutic and
interventional treatment options is warranted.
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Introduction
The majority of newly diagnosed metastases in patients with
breast cancer are discovered between the intervals of regular-
ly scheduled clinical visits. Randomized trials have shown no
superiority of an intensified surveillance including chest X-ray,
bone scans, ultrasound or computed tomography in asympto-
matic patients when compared to a clinical follow-up includ-
ing routine history and physical examination and regularly
scheduled mammograms. Routine examination for metastatic
spread is therefore not recommended in clinically asympto-
matic patients. The statement number 50 of the German S3
Guideline concluded: Laboratory and intensified machine-
aided tests are only recommended for patients with a history
or with symptoms of recurrence or metastatic spread (level of
evidence 1a, grade of recommendation B).
The majority of breast cancer recurrences occur during the
first decade after primary therapy, particularly during years
2–5. However, a much later occurrence is possible [1–4]. Rec-
ommendations regarding surveillance for relapse of disease
are based on international and national guidelines. It has often
been discussed whether an intensified follow-up, including
various laboratory and imaging tests, really improves out-
come. Although intensified surveillance may detect asympto-
matic disease recurrence, 2 major randomized trials and a
Cochrance review have concluded that there is no survival
benefit from more intensive surveillance during post-treat-
ment follow-up [5–7]. In contrast, 70% of the patients recruit-
ed into these trials stated that they wanted to continue regular
clinical visits, even when they are asymptomatic.
The cost of intensive surveillance was addressed in a report
comparing the ‘minimalist approach’ to follow-up of breast
cancer survivors to the ‘maximalist approach’. The estimated
cost of the maximalist approach was 5 times that of the mini-
malist approach (USD 5,735.– vs. USD 1,025.–). The authors
projected that a universal minimalist policy would save nearly
USD 812 million by 1995 [8]. The present investigation was
performed to analyze the patients’ view on the issue of sur-
veillance after diagnosis of breast cancer.
Patients and Methods
A questionnaire was send to 2,000 patients with a history of breast cancer
in Rheinland-Pfalz. The questionnaire used for the present survey includ-
ed 29 questions with a total of 58 variables. The complete questionnaire is
accessible on the homepage of our institution (http://med3.klinikum.uni-
muenchen.de/ycms/Studien_80.htm).
Differences between patient groups were analyzed using the x2-test (Chi-
square test).
Results
A total of 452 patients (22.6%) answered to the questionnaire
and provided the basis for the present evaluation. Nearly one
third of the patients were organized members of a self-help
group (28.1%). The median age was 62 years (range 23–85
years). More than 80% of the surveyed patients were disease-
free at the time of the survey, with the percentage being slight-
ly lower in the organized patient group (70%).
The need for surveillance after therapy was affirmed by the
majority of the patients (fig. 1). When asked about follow-up
tests and examinations regularly offered in the past, most pa-
tients named ultrasound and expansive laboratory tests. There
was a significant difference regarding the frequency of tumor
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Table 1. Tests for surveillance offered to the patients
Tests Patients, % p value (x2-test)

Self-help Non-
group organized
Laboratory tests 88.2 82.5 ns
Tumor marker tests 79.5 56.0 <0.0001
Chest X-ray 55.9 52.0 ns
Ultrasound 81.9 85.5 ns
Bone scan 47.2 35.7 0.02
CT scan 33.8 29.5 ns
PET-CT scan 9.4 12.0 ns
Mammography 86.6 89.2 ns
Physical examination 90.6 85.5 ns
Routine history 93.7 92.9 ns
ns = Not significant; CT = computed tomography; 
PET = positron emission tomography.
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Fig. 1. Is there a need for surveillance after therapy?
marker tests and bone scans which were both offered more
frequently to members of the self-help group (table 1). Two
thirds of patients accept the increased effort of an intensified
surveillance, and one third answered that there is a need for
more technical examinations during follow-up (fig. 2). The
majority of patients would participate in a surveillance study,
but only few would accept participation in a randomized set-
ting (fig. 3). The expectations of an intensified follow-up in-
cluded an increased sense of security and reassurance and, in-
terestingly, a decrease in fear or distress (fig. 4). Moreover,
95% of the consulted patients (94% of self-help group) would
want to be informed earlier of recurrent disease if such an
early diagnosis improves the clinical outcome. And the major-
ity believes that early diagnosis of recurrence, even early diag-
nosis of metastatic spread, will improve survival (97%; 94% of
the organized patients).
Discussion
Except for routine history, physical examination and regu-
larly scheduled mammograms, there are no strong recom-
mendations to implement more intensive surveillance tests
for asymptomatic patients after primary treatment of breast
cancer. Although an intensified follow-up may detect asymp-
tomatic disease recurrence, randomized trials have shown no
survival benefit from more intensive surveillance during
post-treatment follow-up [5–7]. Despite these evidence-
based recommendations, a majority of post-treatment breast
cancer patients recruited on these trials declared that they
want to continue regular clinical visits even when they are
asymptomatic.
It is justified to query the relevance of the above mentioned
trials. Cocconi et al. [9] already demonstrated that the nega-
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Fig. 2. Is the intensity of the present surveillance adequate?
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Fig. 3. Would you accept participation on a surveillance study?
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Fig. 4. Intensification of surveillance leads to …?
tive outcome of those trials was predictable. Major criticism
concerns the largely palliative treatment approach, the ab-
sence of multimodal strategies and the limited options of en-
docrine or chemotherapeutic therapies [9]. Considerable
changes in the endocrine treatment and surgical and interven-
tional radiology procedures (radiofrequency ablation, laser-in-
duced thermotherapy, selective intrahepatic radiotherapy)
have been made in the last decade. It has been demonstrated
that an aggressive surgical approach improves the outcome of
selected patients with oligometastatic breast cancer [10].
These highly selected patients, the majority of whom is diag-
nosed in an asymptomatic stage, may benefit from an intensi-
fied follow-up. Moreover, it is critical to evaluate the impact of
newer surveillance strategies and the early onset of modern
endocrine treatment, such as aromatase inhibitors, on survival.
The present non-representative investigation was initiated to
evaluate the patients’ view on the matter. The results can be
summarized in 3 major categories. Firstly, the expectations of
an intensified follow-up include an increased sense of security
and reassurance but interestingly not an increase in fear or
distress as often stated in more emotional debates. Addition-
ally, one third of the patients wish for more technical efforts in
their surveillance, which was also found in a Dutch study by
De Bock et al. [11]. Secondly, the majority of physicians obvi-
ously do not accept the present follow-up guidelines, as regu-
larly scheduled follow-up visits were expanded using exten-
sive laboratory and imaging tests as demonstrated in table 1.
Interestingly, there is a significant difference in the frequency
of tumor marker testing and bone scans performed in orga-
nized patients as compared to those who are not organized in
self-help groups. Thirdly, there is a large discrepancy between
the present evidence-based facts and the expectations of the
afflicted patients, since the majority of them believe in the
positive impact of early diagnosis of recurrence on survival.
It is time to initiate a new surveillance study which investigat-
ing the efficacy of an intensified surveillance based on the im-
proved possibilities of modern diagnostics and endocrine, im-
munotherapeutic, chemotherapeutic and interventional treat-
ment options. Not only physicians but also the patients are pre-
pared to re-analyze this important field of oncological activity.
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